APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic SGLT-2 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antidiabetic SGLT-2 Inhibitor Market Analysis and Forecast 2026-2032

20 December 2025192 pages

Choose your research edition.

Industry ResearchAntidiabetic SGLT-2 Inhibitor Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic SGLT-2 Inhibitor Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Antidiabetic SGLT-2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic SGLT-2 Inhibitor Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic SGLT-2 Inhibitor Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Antidiabetic SGLT-2 Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Antidiabetic SGLT-2 Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antidiabetic SGLT-2 Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antidiabetic SGLT-2 Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antidiabetic SGLT-2 Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Antidiabetic SGLT-2 Inhibitor include Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, Servier Laboratories, AstraZeneca, GlaxoSmithKline, Pfizer, Eli Lilly and Merck & Co, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Antidiabetic SGLT-2 Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antidiabetic SGLT-2 Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Antidiabetic SGLT-2 Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antidiabetic SGLT-2 Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antidiabetic SGLT-2 Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Antidiabetic SGLT-2 Inhibitor sales, projected growth trends, production technology, application and end-user industry.

Antidiabetic SGLT-2 Inhibitor Segment by Company

Boehringer Ingelheim

Bristol-Myers Squibb

Novo Nordisk

Servier Laboratories

AstraZeneca

GlaxoSmithKline

Pfizer

Eli Lilly

Merck & Co

Johnson & Johnson

Sanofi

Takeda Pharmaceuticals

Antidiabetic SGLT-2 Inhibitor Segment by Type

Canagliflozin

Dapagliflozin

Empagliflozin

Other

Antidiabetic SGLT-2 Inhibitor Segment by Application

Hospitals

Clinics

Other

Antidiabetic SGLT-2 Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic SGLT-2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic SGLT-2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic SGLT-2 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Antidiabetic SGLT-2 Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Antidiabetic SGLT-2 Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antidiabetic SGLT-2 Inhibitor sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Canagliflozin Major Manufacturers Table 3. Dapagliflozin Major Manufacturers Table 4. Empagliflozin Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals Major Manufacturers Table 8. Clinics Major Manufacturers Table 9. Other Major Manufacturers Table 10. Antidiabetic SGLT-2 Inhibitor Industry Trends Table 11. Antidiabetic SGLT-2 Inhibitor Industry Drivers Table 12. Antidiabetic SGLT-2 Inhibitor Industry Opportunities and Challenges Table 13. Antidiabetic SGLT-2 Inhibitor Industry Restraints Table 14. Global Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2021-2026) Table 18. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2027-2032) Table 19. Global Antidiabetic SGLT-2 Inhibitor Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2021-2026) & (K Units) Table 21. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2027-2032) & (K Units) Table 22. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2021-2026) Table 23. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2027-2032) Table 24. Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 28. Global Antidiabetic SGLT-2 Inhibitor Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Antidiabetic SGLT-2 Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Antidiabetic SGLT-2 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Antidiabetic SGLT-2 Inhibitor Manufacturers, Product Type & Application Table 32. Global Antidiabetic SGLT-2 Inhibitor Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Antidiabetic SGLT-2 Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2021-2026) Table 39. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2027-2032) Table 40. Global Antidiabetic SGLT-2 Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 42. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 43. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2021-2026) Table 44. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2027-2032) Table 45. Global Antidiabetic SGLT-2 Inhibitor Price by Type (2021-2026) & (US$/Unit) Table 46. Global Antidiabetic SGLT-2 Inhibitor Price by Type (2027-2032) & (US$/Unit) Table 47. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2021-2026) Table 51. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2027-2032) Table 52. Global Antidiabetic SGLT-2 Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 54. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 55. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2021-2026) Table 56. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2027-2032) Table 57. Global Antidiabetic SGLT-2 Inhibitor Price by Application (2021-2026) & (US$/Unit) Table 58. Global Antidiabetic SGLT-2 Inhibitor Price by Application (2027-2032) & (US$/Unit) Table 59. Boehringer Ingelheim Company Information Table 60. Boehringer Ingelheim Business Overview Table 61. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 63. Boehringer Ingelheim Recent Development Table 64. Bristol-Myers Squibb Company Information Table 65. Bristol-Myers Squibb Business Overview Table 66. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 68. Bristol-Myers Squibb Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. Servier Laboratories Company Information Table 75. Servier Laboratories Business Overview Table 76. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 78. Servier Laboratories Recent Development Table 79. AstraZeneca Company Information Table 80. AstraZeneca Business Overview Table 81. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 83. AstraZeneca Recent Development Table 84. GlaxoSmithKline Company Information Table 85. GlaxoSmithKline Business Overview Table 86. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 88. GlaxoSmithKline Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 93. Pfizer Recent Development Table 94. Eli Lilly Company Information Table 95. Eli Lilly Business Overview Table 96. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 98. Eli Lilly Recent Development Table 99. Merck & Co Company Information Table 100. Merck & Co Business Overview Table 101. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 103. Merck & Co Recent Development Table 104. Johnson & Johnson Company Information Table 105. Johnson & Johnson Business Overview Table 106. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 108. Johnson & Johnson Recent Development Table 109. Sanofi Company Information Table 110. Sanofi Business Overview Table 111. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 113. Sanofi Recent Development Table 114. Takeda Pharmaceuticals Company Information Table 115. Takeda Pharmaceuticals Business Overview Table 116. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 118. Takeda Pharmaceuticals Recent Development Table 119. North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 120. North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 121. North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 122. North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 123. North America Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 124. North America Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 125. North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 126. North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 127. North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 128. North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 129. North America Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 130. North America Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 131. North America Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 133. North America Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 134. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 135. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 136. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 137. North America Antidiabetic SGLT-2 Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 138. North America Antidiabetic SGLT-2 Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 139. United States Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 140. Canada Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 141. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 142. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 143. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 144. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 145. Europe Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 146. Europe Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 147. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 148. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 149. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 150. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 151. Europe Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 152. Europe Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 153. Europe Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Europe Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 155. Europe Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 156. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 157. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 158. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 159. Europe Antidiabetic SGLT-2 Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 160. Europe Antidiabetic SGLT-2 Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 161. Germany Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 162. France Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 163. U.K. Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 164. Italy Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 165. Netherlands Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 166. Nordic Countries Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 167. China Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 168. China Antidiabetic SGLT-2 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 169. China Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 170. China Antidiabetic SGLT-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 171. China Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 172. China Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 173. China Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 174. China Antidiabetic SGLT-2 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 175. China Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 176. China Antidiabetic SGLT-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 177. China Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 178. China Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 179. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 180. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 181. Asia Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 182. Asia Antidiabetic SGLT-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 183. Asia Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 184. Asia Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 185. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 186. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 187. Asia Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 188. Asia Antidiabetic SGLT-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 189. Asia Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 190. Asia Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 191. Asia Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 192. Asia Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 193. Asia Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 194. Asia Antidiabetic SGLT-2 Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 195. Asia Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 196. Asia Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 197. Asia Antidiabetic SGLT-2 Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 198. Asia Antidiabetic SGLT-2 Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 199. Japan Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 200. South Korea Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 201. India Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 202. Australia Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 203. China Taiwan Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 204. Southeast Asia Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 205. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 206. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 207. SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 208. SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 209. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 210. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 211. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 212. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 213. SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 214. SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 215. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 216. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 217. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 218. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 219. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 220. SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 221. SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 222. SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 223. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 224. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 225. Brazil Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 226. Argentina Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 227. Chile Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 228. Colombia Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 229. Peru Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 230. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 231. Israel Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 232. UAE Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 233. Turkey Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 234. Iran Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 235. Egypt Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Table 236. Key Raw Materials Table 237. Raw Materials Key Suppliers Table 238. Antidiabetic SGLT-2 Inhibitor Distributors List Table 239. Antidiabetic SGLT-2 Inhibitor Customers List Table 240. Research Programs/Design for This Report Table 241. Authors List of This Report Table 242. Secondary Sources Table 243. Primary Sources List of Figures Figure 1. Antidiabetic SGLT-2 Inhibitor Image Figure 2. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic SGLT-2 Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Canagliflozin Image Figure 5. Dapagliflozin Image Figure 6. Empagliflozin Image Figure 7. Other Image Figure 8. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Antidiabetic SGLT-2 Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals Image Figure 11. Clinics Image Figure 12. Other Image Figure 13. Global Antidiabetic SGLT-2 Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 15. Global Antidiabetic SGLT-2 Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2021-2032) Figure 18. Global Antidiabetic SGLT-2 Inhibitor Sales (2021-2032) & (K Units) Figure 19. Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Antidiabetic SGLT-2 Inhibitor Sales YoY (2021-2032) & (K Units) Figure 22. Europe Antidiabetic SGLT-2 Inhibitor Sales YoY (2021-2032) & (K Units) Figure 23. China Antidiabetic SGLT-2 Inhibitor Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Antidiabetic SGLT-2 Inhibitor Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales YoY (2021-2032) & (K Units) Figure 26. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2021-2032) Figure 32. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2021-2032) Figure 35. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2021-2032) Figure 38. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2021-2032) Figure 41. North America Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2021-2032) Figure 42. North America Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2021-2032) Figure 43. North America Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2021-2032) Figure 44. North America Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2021-2032) Figure 45. North America Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2021-2032) Figure 46. North America Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2021-2032) Figure 47. Europe Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2021-2032) Figure 48. Europe Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2021-2032) Figure 49. Europe Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2021-2032) Figure 50. Europe Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2021-2032) Figure 51. Europe Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2021-2032) Figure 52. Europe Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2021-2032) Figure 53. China Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2021-2032) Figure 54. China Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2021-2032) Figure 55. China Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2021-2032) Figure 56. China Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2021-2032) Figure 57. Asia Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2021-2032) Figure 58. Asia Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2021-2032) Figure 59. Asia Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2021-2032) Figure 60. Asia Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2021-2032) Figure 61. Asia Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2021-2032) Figure 62. Asia Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2021-2032) Figure 63. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2021-2032) Figure 64. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2021-2032) Figure 65. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2021-2032) Figure 66. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2021-2032) Figure 67. SAMEA Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2021-2032) Figure 68. SAMEA Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2021-2032) Figure 69. Antidiabetic SGLT-2 Inhibitor Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Antidiabetic SGLT-2 Inhibitor Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Canagliflozin
  • Dapagliflozin
  • Empagliflozin
  • Other
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novo Nordisk
  • Servier Laboratories
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Merck & Co
  • Johnson & Johnson
  • Sanofi
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antidiabetic SGLT-2 Inhibitor Market by Type
  3. 1.2.1 Global Antidiabetic SGLT-2 Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Canagliflozin
  5. 1.2.3 Dapagliflozin
  6. 1.2.4 Empagliflozin
  7. 1.2.5 Other
  8. 1.3 Antidiabetic SGLT-2 Inhibitor Market by Application
  9. 1.3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals
  11. 1.3.3 Clinics
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Antidiabetic SGLT-2 Inhibitor Market Dynamics
  1. 2.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
  2. 2.2 Antidiabetic SGLT-2 Inhibitor Industry Drivers
  3. 2.3 Antidiabetic SGLT-2 Inhibitor Industry Opportunities and Challenges
  4. 2.4 Antidiabetic SGLT-2 Inhibitor Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Antidiabetic SGLT-2 Inhibitor Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region
  3. 3.2.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2021-2026)
  5. 3.2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2027-2032)
  6. 3.2.4 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Antidiabetic SGLT-2 Inhibitor Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Antidiabetic SGLT-2 Inhibitor Sales by Region
  9. 3.4.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2021-2026)
  11. 3.4.3 Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2027-2032)
  12. 3.4.4 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers
  2. 4.1.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Antidiabetic SGLT-2 Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers
  6. 4.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Antidiabetic SGLT-2 Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Antidiabetic SGLT-2 Inhibitor Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Antidiabetic SGLT-2 Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Antidiabetic SGLT-2 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Antidiabetic SGLT-2 Inhibitor Manufacturers, Product Type & Application
  13. 4.7 Global Antidiabetic SGLT-2 Inhibitor Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Antidiabetic SGLT-2 Inhibitor Market CR5 and HHI
  16. 4.8.2 2025 Antidiabetic SGLT-2 Inhibitor Tier 1, Tier 2, and Tier 3
5 Antidiabetic SGLT-2 Inhibitor Market by Type
  1. 5.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type
  2. 5.1.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Type
  6. 5.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2021-2032)
  9. 5.3 Global Antidiabetic SGLT-2 Inhibitor Price by Type
6 Antidiabetic SGLT-2 Inhibitor Market by Application
  1. 6.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application
  2. 6.1.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Application
  6. 6.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2021-2032)
  9. 6.3 Global Antidiabetic SGLT-2 Inhibitor Price by Application
7 Company Profiles
  1. 7.1 Boehringer Ingelheim
  2. 7.1.1 Boehringer Ingelheim Company Information
  3. 7.1.2 Boehringer Ingelheim Business Overview
  4. 7.1.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio
  6. 7.1.5 Boehringer Ingelheim Recent Developments
  7. 7.2 Bristol-Myers Squibb
  8. 7.2.1 Bristol-Myers Squibb Company Information
  9. 7.2.2 Bristol-Myers Squibb Business Overview
  10. 7.2.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio
  12. 7.2.5 Bristol-Myers Squibb Recent Developments
  13. 7.3 Novo Nordisk
  14. 7.3.1 Novo Nordisk Company Information
  15. 7.3.2 Novo Nordisk Business Overview
  16. 7.3.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio
  18. 7.3.5 Novo Nordisk Recent Developments
  19. 7.4 Servier Laboratories
  20. 7.4.1 Servier Laboratories Company Information
  21. 7.4.2 Servier Laboratories Business Overview
  22. 7.4.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio
  24. 7.4.5 Servier Laboratories Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 GlaxoSmithKline
  32. 7.6.1 GlaxoSmithKline Company Information
  33. 7.6.2 GlaxoSmithKline Business Overview
  34. 7.6.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio
  36. 7.6.5 GlaxoSmithKline Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Eli Lilly
  44. 7.8.1 Eli Lilly Company Information
  45. 7.8.2 Eli Lilly Business Overview
  46. 7.8.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio
  48. 7.8.5 Eli Lilly Recent Developments
  49. 7.9 Merck & Co
  50. 7.9.1 Merck & Co Company Information
  51. 7.9.2 Merck & Co Business Overview
  52. 7.9.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio
  54. 7.9.5 Merck & Co Recent Developments
  55. 7.10 Johnson & Johnson
  56. 7.10.1 Johnson & Johnson Company Information
  57. 7.10.2 Johnson & Johnson Business Overview
  58. 7.10.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio
  60. 7.10.5 Johnson & Johnson Recent Developments
  61. 7.11 Sanofi
  62. 7.11.1 Sanofi Company Information
  63. 7.11.2 Sanofi Business Overview
  64. 7.11.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio
  66. 7.11.5 Sanofi Recent Developments
  67. 7.12 Takeda Pharmaceuticals
  68. 7.12.1 Takeda Pharmaceuticals Company Information
  69. 7.12.2 Takeda Pharmaceuticals Business Overview
  70. 7.12.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio
  72. 7.12.5 Takeda Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Antidiabetic SGLT-2 Inhibitor Market Size by Type
  2. 8.1.1 North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2032)
  3. 8.1.2 North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032)
  4. 8.1.3 North America Antidiabetic SGLT-2 Inhibitor Price by Type (2021-2032)
  5. 8.2 North America Antidiabetic SGLT-2 Inhibitor Market Size by Application
  6. 8.2.1 North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2032)
  7. 8.2.2 North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032)
  8. 8.2.3 North America Antidiabetic SGLT-2 Inhibitor Price by Application (2021-2032)
  9. 8.3 North America Antidiabetic SGLT-2 Inhibitor Market Size by Country
  10. 8.3.1 North America Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Antidiabetic SGLT-2 Inhibitor Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Type
  2. 9.1.1 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2032)
  3. 9.1.2 Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032)
  4. 9.1.3 Europe Antidiabetic SGLT-2 Inhibitor Price by Type (2021-2032)
  5. 9.2 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Application
  6. 9.2.1 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2032)
  7. 9.2.2 Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032)
  8. 9.2.3 Europe Antidiabetic SGLT-2 Inhibitor Price by Application (2021-2032)
  9. 9.3 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Country
  10. 9.3.1 Europe Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Antidiabetic SGLT-2 Inhibitor Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Antidiabetic SGLT-2 Inhibitor Market Size by Type
  2. 10.1.1 China Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2032)
  3. 10.1.2 China Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032)
  4. 10.1.3 China Antidiabetic SGLT-2 Inhibitor Price by Type (2021-2032)
  5. 10.2 China Antidiabetic SGLT-2 Inhibitor Market Size by Application
  6. 10.2.1 China Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2032)
  7. 10.2.2 China Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032)
  8. 10.2.3 China Antidiabetic SGLT-2 Inhibitor Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antidiabetic SGLT-2 Inhibitor Market Size by Type
  2. 11.1.1 Asia Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2032)
  3. 11.1.2 Asia Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032)
  4. 11.1.3 Asia Antidiabetic SGLT-2 Inhibitor Price by Type (2021-2032)
  5. 11.2 Asia Antidiabetic SGLT-2 Inhibitor Market Size by Application
  6. 11.2.1 Asia Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2032)
  7. 11.2.2 Asia Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032)
  8. 11.2.3 Asia Antidiabetic SGLT-2 Inhibitor Price by Application (2021-2032)
  9. 11.3 Asia Antidiabetic SGLT-2 Inhibitor Market Size by Country
  10. 11.3.1 Asia Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Antidiabetic SGLT-2 Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Antidiabetic SGLT-2 Inhibitor Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antidiabetic SGLT-2 Inhibitor Market Size by Type
  2. 12.1.1 SAMEA Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Antidiabetic SGLT-2 Inhibitor Price by Type (2021-2032)
  5. 12.2 SAMEA Antidiabetic SGLT-2 Inhibitor Market Size by Application
  6. 12.2.1 SAMEA Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Antidiabetic SGLT-2 Inhibitor Price by Application (2021-2032)
  9. 12.3 SAMEA Antidiabetic SGLT-2 Inhibitor Market Size by Country
  10. 12.3.1 SAMEA Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Antidiabetic SGLT-2 Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Antidiabetic SGLT-2 Inhibitor Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Antidiabetic SGLT-2 Inhibitor Value Chain Analysis
  2. 13.1.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Antidiabetic SGLT-2 Inhibitor Production Mode & Process
  6. 13.2 Antidiabetic SGLT-2 Inhibitor Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Antidiabetic SGLT-2 Inhibitor Distributors
  9. 13.2.3 Antidiabetic SGLT-2 Inhibitor Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst